NCT01705340: Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery |
|
|
| Terminated | 1 | 60 | US | Akt inhibitor MK2206, MK2206, trastuzumab, anti-c-erB-2, Herceptin, MOAB HER2, lapatinib ditosylate, GSK572016, GW-572016, GW2016, Lapatinib, Tykerb, laboratory biomarker analysis | National Cancer Institute (NCI) | Adenocarcinoma of the Gastroesophageal Junction, HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Recurrent Esophageal Cancer, Recurrent Gastric Cancer, Stage IIIC Breast Cancer, Stage IIIC Esophageal Cancer, Stage IIIC Gastric Cancer, Stage IV Breast Cancer, Stage IV Esophageal Cancer, Stage IV Gastric Cancer | 05/13 | | | |
